Alirocumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09302 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | ichthyosis, X-linked, without steroid sulfatase deficiency | KG + DL |
| 2 | disorder of other vitamins and cofactors metabolism and transport | KG + DL |
| 3 | xanthomatosis (disease) | KG + DL |
| 4 | 46,XY disorder of sexual development due to dihydrotestosterone backdoor pathway biosynthesis defect | KG + DL |
| 5 | cholesterol catabolic process disease | KG + DL |
| 6 | 46,XY disorder of sex development due to a cholesterol synthesis defect | KG + DL |
| 7 | dappled diaphyseal dysplasia | KG + DL |
| 8 | neutral lipid storage disease | KG + DL |
| 9 | 3-hydroxyacyl-CoA dehydrogenase deficiency | KG + DL |
| 10 | spastic paraplegia-optic atrophy-neuropathy and spastic paraplegia-optic atrophy-neuropathy-related disorder | KG + DL |
| 11 | thrombocytopenic purpura | KG + DL |
| 12 | chondrodysplasia punctata, brachytelephalangic, autosomal | KG + DL |
| 13 | chondrodysplasia punctata, tibial-metacarpal type | KG + DL |
| 14 | Astley-Kendall dysplasia | KG + DL |
| 15 | spastic paraplegia | KG + DL |
| 16 | adenosine deaminase deficiency | KG + DL |
| 17 | hemorrhagic disease of newborn | KG + DL |
| 18 | familial apolipoprotein C-II deficiency | KG + DL |
| 19 | severe combined immunodeficiency due to LCK deficiency | KG + DL |
| 20 | reticular dysgenesis | KG + DL |
| 21 | disorder of phospholipids, sphingolipids and fatty acids biosynthesis | KG + DL |
| 22 | glaucoma | KG + DL |
| 23 | syndrome with combined immunodeficiency | KG + DL |
| 24 | peliosis hepatis | KG + DL |
| 25 | stone in bladder diverticulum | KG + DL |
| 26 | hepatic infarction | KG + DL |
| 27 | symptomatic form of hemophilia in female carriers | KG + DL |
| 28 | disease of catalytic activity | KG + DL |
| 29 | pre-malignant neoplasm | KG + DL |
| 30 | autosomal ichthyosis syndrome with prominent neurologics signs | KG + DL |
| 31 | cataract associated with a metabolic disease | KG + DL |
| 32 | bronchial adenomas/carcinoids childhood | KG + DL |
| 33 | non-seminomatous lesion | KG + DL |
| 34 | ductal or ductular proliferation | KG + DL |
| 35 | chondroid hamartoma | KG + DL |
| 36 | tumor of testis and paratestis | KG + DL |
| 37 | odontogenic cyst | KG + DL |
| 38 | thyroglossal duct cyst | KG + DL |
| 39 | mesenchymoma | KG + DL |
| 40 | kidney pelvis sarcomatoid transitional cell carcinoma | KG + DL |
| 41 | renal pelvis papillary urothelial carcinoma | KG + DL |
| 42 | cystic neoplasm | KG + DL |
| 43 | benign neoplasm of tongue | KG + DL |
| 44 | prostatic urethra urothelial carcinoma | KG + DL |
| 45 | metabolic disease with cataract | KG + DL |
| 46 | nasopharyngeal teratoma | KG + DL |
| 47 | infiltrating bladder urothelial carcinoma sarcomatoid variant | KG + DL |
| 48 | non-syndromic esophageal malformation | KG + DL |
| 49 | cervical neuroblastoma | KG + DL |
| 50 | lipoma of the conjunctiva | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.